Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging

Not Applicable

Completed

• Conditions: Type II Diabetes
• Interventions: Drug: GLP-1 agonists; Procedure: Cardiac MRI; Other: Follow up by phone

• Registration Number: NCT03498001
• Lead Sponsor: Centre Hospitalier Universitaire Dijon

Brief Summary

Type II diabetes is a known risk factor for heart failure, particularly through the progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including myocardial steatosis and epicardial fat, are altered in diabetic patients. The development of new anti-diabetics (incretins) has demonstrated protective cardiovascular effects independent of effects on glycemic control for the first time in the history of these therapies. Thus Glucagon-Like Peptide 1 (GLP-1) agonists improve the recovery of cardiac function after a heart attack and decrease atheromatous processes. It has also been demonstrated in a diabetic rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of myocardial steatosis associated with beneficial cardiac molecular remodeling involving pro-apoptotic, oxidative and metabolic processes. These beneficial cardiovascular effects were observed in the absence of any changes in blood glucose, insulin levels or body weight.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-03-30
• Study First Submitted QC: 2018-04-06
• Study First Posted: 2018-04-13
• Study Start: 2018-04-16
• Primary Completion: 2023-06-06
• Study Completion: 2023-12-20
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-16
• Last Update Posted: 2024-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Patient who has given his consent
• Adult patient over 50 years of age Type II diabetic treated without modification of the antidiabetic treatment during the previous 3 months
• HbA1c ≥ 7%.
• Patient for whom a decision to start a GLP-1 agonist treatment has been made (Liraglutide, Semaglutide, Dulaglutide).
• At least one risk factor from among:
• Treated hypertension,
• treated dyslipidemia,
• History of obesity (BMI>30 kg/m2)
• Active smoking (from 1 cigarette per day) or smoking cessation for less than 3 years,
• Coronary heredity (myocardial infarction or sudden death before age 55 in father/brother, myocardial infarction or sudden death before age 65 in mother/sister)

Exclusion Criteria

• Protected adult Patient not affiliated to a national health insurance scheme Pregnant or breastfeeding woman Women who intend to become pregnant or of childbearing age and do not use adequate contraceptive methods.

Antidiabetic treatment of the incretin family (DPP4 inhibitor except sitagliptin) Severe renal failure (clearance <30ml/min according to Cockroft due to gadolinium injection) Claustrophobia / contraindication to MRI (compatible non-MRI implanted metallic material) History of hypersensitivity to gadoteric acid or gadolinium-based contrast agents and meglumine Hypersensitivity to Liraglutide, Semaglutide, Dulaglutide or any of the excipients History or presence of pancreatitis (acute or chronic) Chronic inflammatory bowel disease Diabetic gastroparesis Dysthyroidism

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients	Cardiac MRI	-
Patients	Follow up by phone	-
Patients	GLP-1 agonists	-

Primary Outcome Measures

Name	Time	Method
Change from Baseline Concentration of intramyocardial triglycerides at 6 months	Month 6	Intramyocardial triglyceride concentration, expressed in %, evaluated by NMR spectroscopy

Trial Locations

Locations (1)

Chu Dijon Bourgogne; 🇫🇷 Dijon, France